IMAP advised Atrys has acquired 100% of the shares of Swiss firm, Radio-Onkologie Amsler AG. Founded in 2003 by Dr. Amsler, Radio-Onkologie Amsler offers advanced radiotherapy treatments for oncology patients through its two clinics in the Basel region of Switzerland. The company is the main private provider of such services in the region, with two lineal accelerators providing over 800 treatments to patients per year.

In 2020, the company reached an IFRS EBITDA of €3 million. Atrys is a Spanish biomedical company dedicated to providing diagnostic services and medical treatments primarily for oncology patients. Its activity encompasses three main areas: diagnostic laboratory (50%), telemedicine (39%) and radiotherapy (11%). Atrys is listed on the BME Growth Stock Exchange under the ticker ATRY and has a market capitalization of €330 million. The acquisition is part of Atrys’ long-term strategy in which it is looking to create a pan-European network of oncology clinics for high precision radiotherapy treatments and scale R&D for hypofractionated radiotherapy.

This is Atrys’ first acquisition in Switzerland allowing it to enter a new market and add to its existing radiotherapy operations in Portugal and Spain. The resulting company will have a total of 11 lineal accelerators. Going forward, the founder and CEO of the acquired company, Dr. Amsler, will remain on board to ensure a smooth transition.

The Degroof Petercam team, led by Oriol Huguet, acted as a financial advisor to Atrys. The team carried out an extensive European market screening and identified Radio-Onkologie Amsler as a well-suited acquisition target for Atrys. Degroof Petercam relied on the valuable assistance of IMAP Germany to make initial contacts with the target and coordinate the overall flow of the transaction towards a successful closing.